Madrigal Pharmaceuticals
$499.71Change from previous close: −0.84%Absolute change: −$4.25
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $11.55B
- Enterprise value
- $11.05B
- Forward P/E
- 51.9
- Price/book
- 22.0
- Price/sales
- 8.99
- EV/EBITDA
- -34.4
- EV/revenue
- 8.61
Profitability and growth
- Gross margin
- 91.5%
- Operating margin
- -15.5%
- Net margin
- -25.3%
- ROE
- -53.3%
- ROA
- -17.8%
- Revenue growth (year over year)
- 71.2%
Financial health
- Total cash
- $838.75M
- Total debt
- $347.75M
- Debt/equity
- 0.66
- Current ratio
- 3.21
- Quick ratio
- 2.76
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $682.11
- Median price target
- $661.00
- High price target
- $962.00
- Low price target
- $543.00
- Analysts with a price target
- 18
- Consensus
- Strong buy
- Forward EPS
- $9.63
- EPS estimate, current year
- -$6.49
Shares and trading
- Beta
- -0.99
- Average volume
- 292.52K
- Shares outstanding
- 23.1M
- Float
- 13.72M
- Institutional ownership
- 104.6%
- Insider ownership
- 5.8%
- Short interest (% of float)
- 11.5%
- Short ratio (days)
- 10.2